Vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) are important targets of cancer therapy, and inhibition of VEGF and VEGFR has been proven to be effective against advanced NSCLC in several studies [13,14]. The gene discussed is KDR; the disease is non-small cell lung carcinoma.